VTYX Q4 2024 Earnings — Ventyx Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

VTYXVentyx Biosciences, Inc.

$1B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$32M

Net Income

-$29M

EPS (Diluted)

$-0.41

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$23M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$277M

Total Liabilities

$23M

Stockholders' Equity

$254M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$32M	-$50M	+35.6%
Net Income	-$29M	-$47M	+37.2%